U.S. Sen. Harkin: Questions FDA in wake of Johnson & Johnson children's drug recall

U.S. Sen. Harkin: Questions FDA in wake of Johnson & Johnson children's drug recall

FOR IMMEDIATE RELEASE CONTACT: Kate Cyrul / Bergen Kenny May 24, 2010 (202) 224-3254

WASHINGTON, D.C. - Senator Tom Harkin (D-IA) today sent a letter to Food and Drug Administration (FDA) Commissioner Margaret Hamburg, M.D., following the recall of 40 varieties of childrens' and infants' formulations of Tylenol, Motrin, Zyrtec and Benadryl by Johnson & Johnson's McNeil Consumer Healthcare. Harkin, who is Chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee that has jurisdiction over the FDA, posed questions regarding the recall, events leading up to it and consumer complaints. Johnson & Johnson has had problems associated with these products over the past two years. Harkin also asked the agency if additional regulatory action is needed to prevent further recalls.

"I commend you for FDA's leadership in responding to this crisis, both in terms of your outreach to the public and your increased regulatory activity," Harkin wrote. "However, I am interested in ensuring that, as a public health agency whose mission is to protect the American public, you have sufficient authority to prevent and respond to contamination of the drug supply. I am especially concerned because so many of the drugs at issue in this recall were intended for infants and children."

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.